Clinical trials: Obinutuzumab, open to volunteers
Follicular Lymphoma
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Prospective, multicenter, open label, phase III randomized clinical trial in previously untreated Follicular Lymphoma in early stage. Patients will be randomized to receive Radiotherapy or Radiotherapy plus Obinutuzumab.
- Trial name
- FIL_GAZEBO (NCT05929222)
- Testing
- Radiotherapy, Radiotherapy plus Obinutuzumab
- Where
- 49 sites in Italy
- Volunteers
- 190 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lupus Nephritis, Systemic Lupus Erythematosus (SLE)
Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
This is a randomised, open label, controlled non-inferiority phase III multicentre trial. As primary objective, the study aims to demonstrate that a regimen free of additional oral corticosteroids but with obinutuzumab (and MMF)…
- Trial name
- OBILUP (NCT04702256)
- Testing
- Obinutuzumab administration, Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil, Administration of methylprednisolone, paracetamol and dexchlorpheniramine
- Where
- France
- Volunteers
- 196 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Follicular Lymphoma ( FL)
Zanubrutinib Combined With G-CVP in Previously Untreated FL
The goal of this clinical trial is to learn the efficacy and safety of zanubrutinib in combination with G-CVP in previously untreated follicular lymphoma patients The main questions it aims to answer are: (1) Efficacy and safety…
- Trial name
- NCT06959732
- Testing
- zanubrutinib, obinutuzumab,combined with CVP
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
BTK Inhibitors, Follicular Lymphoma
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Previously untreated patients with follicular lymphoma are treated with the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles.
- Conditions
- BTK Inhibitors, Follicular Lymphoma, Immunochemotherapy
- Trial name
- NCT06918015
- Testing
- ZGCVP
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Zhejiang Cancer Hospital
Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia
Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL
This is a Phase 1b and 2, open-label, single-arm study evaluating the safety, tolerability, and efficacy of roginolisib (IOA-244) in combination with obinutuzumab followed by venetoclax in patients with relapsed or refractory…
- Trial name
- NCT07847957
- Testing
- Roginolisib, Obinutuzumab, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
This phase Ib trial tests the safety and side effects of glofitamab after pre-treatment with obinutuzumab and how well they work in treating patients with central nervous system (CNS) lymphoma.
- Trial name
- NCT06922604
- Testing
- Biospecimen Collection, Computed Tomography, Glofitamab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
DLBCL - Diffuse Large B Cell Lymphoma
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
- Trial name
- NCT07326371
- Testing
- Glofitamab, Obinutuzumab, Axicabtagene Ciloleucel
- Volunteers
- 24 people
- Sponsor
- Ruijin Hospital
Chronic Lymphocytic Leukemia
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Trial name
- NCT05943496
- Testing
- Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- OHSU Knight Cancer Institute
PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma
Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma
This study is being done to find out whether the combination of glofitamab, gemcitabine and oxaliplatin (GemOx) works and is safe in people whose lymphoma has come back or has not responded to previous treatment and has spread to…
- Conditions
- PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
- Trial name
- NCT07888621
- Testing
- Glofitamab, Gemcitabine, Oxaliplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Nephrotic Syndrome，Idiopathic
Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome
This is a multicenter, open-label, single-arm Phase II clinical trial designed to evaluate the safety, efficacy, and immunological effects of obinutuzumab in adult patients with multi-relapsing, rituximab-dependent…
- Trial name
- OASIS (NCT07233330)
- Testing
- Obinutuzumab
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Lupus Nephritis, Membranous Nephropathy
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
Lupus nephritis (LN) is a frequent and severe complication of systemic lupus erythematosus, with important mortality and morbidity.
- Trial name
- OBLUMEN (NCT07721363)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis in Adults
Obinutuzumab in Systemic Sclerosis
The purpose of this study is to determine if obinutuzumab is effective in systemic sclerosis
- Trial name
- OBINUSS (NCT07842523)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Fibrillary Glomerulonephritis
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
- Trial name
- NCT06295770
- Testing
- Obinutuzumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Follicular Lymphoma Grade 3A
Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
This is a multicenter, phase 2, randomized trial to evaluate the efficacy and safety of obinutuzumab with CHOP versus obinutuzumab with bendamustine in treatment-naïve follicular lymphoma (Grade 3A) patients.
- Trial name
- PROOF (NCT06961500)
- Testing
- Obinutuzumab, CHOP, Bendamustine
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Sun Yat-sen University
CLL (Chronic Lymphocytic Leukemia)
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
The evidence base in support of fixed-duration, first-line approaches in medically fit patients with CLL is clearly strengthening, whether through combining targeted agents with immunochemotherapy or through chemotherapy-free…
- Trial name
- PACIFIC (NCT07624799)
- Testing
- Pirtobrutinib, Fludarabine, Cyclophosphamide
- Volunteers
- 82 people
- Sponsor
- French Innovative Leukemia Organisation
Membranous Nephropathy - PLA2R Induced
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study
Objective: To assess the disappearance rate (half-life) of anti-PLA2R antibodies in high-risk primary membranous nephropathy (pMN) patients treated with obinutuzumab (OBI), and to evaluate immunological and clinical remission…
- Trial name
- NCT07163611
- Testing
- Obinutuzumab administration
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT07520006
- Testing
- NX-5948, venetoclax, rituximab
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- Nurix Therapeutics, Inc.
Indolent Lymphoma
Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma
To explore the maximum tolerated dose (MTD) of pomalidomide in combination with obinutuzumab in patients with relapsed/refractory indolent lymphomas (including follicular lymphoma, marginal zone lymphoma, and chronic lymphocytic…
- Trial name
- GP-1 (NCT07441954)
- Testing
- Induction therapy of GP(Pomalidomide+Obinutuzumab）, maintenance therapy of GP(Pomalidomide+Obinutuzumab）
- Volunteers
- 53 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and…
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06649812
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 115 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia (CLL)
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination…
- Trial name
- VeRVe (NCT03342144)
- Where
- 74 sites in Austria, Germany and 1 more
- Volunteers
- 500 people
- Sponsor
- AbbVie